HEMPHARMA Selected as Preliminary Unicorn by Ministry of SMEs and Startups... Scheduled for KOSDAQ Listing

[Asia Economy Reporter Park So-yeon] HEM Pharma announced on the 5th that it has been selected as a special guarantee support target company for the Preliminary Unicorn program by the Ministry of SMEs and Startups.

The Preliminary Unicorn special guarantee is a system that discovers and supports companies with high potential to grow into unicorn companies (startups valued at over 1 trillion KRW). The Korea Technology Finance Corporation provides special guarantees up to 20 billion KRW. This year, a total of 76 companies applied for the Preliminary Unicorn selection, and 20 companies were finally selected.

A representative of HEM Pharma said, "In this evaluation, we received recognition for the business performance and growth potential of our personalized health functional food and service improvement business model utilizing PMAS (Pharmaceutical Meta-Analytical Screening) technology, resulting in a favorable outcome."

The PMAS method is a technique that creates a replica gut environment similar to the intestinal environment using an individual's feces and screens intestinal microorganisms. Through this, it recommends customized probiotics.

HEM Pharma has continuously promoted a personalized solution business using the PMAS method, and in May, it officially launched the personalized microbiome solution 'my LAB by Nutrilite' (hereinafter referred to as my LAB) in collaboration with Amway Korea, accelerating its business.

HEM Pharma plans to utilize the special guarantee support from the Korea Technology Finance Corporation, obtained through the Preliminary Unicorn selection, for facility expansion and service improvement. Additionally, as it is preparing for an initial public offering (IPO), it plans to actively use the pre-diagnosis advisory services of the Korea Technology Finance Corporation.

Joseph Ji, CEO of HEM Pharma, said, "As we are dedicated to research and development with the vision of restoring healthy lives to people suffering from microbiome imbalances, we will accelerate not only personalized healthcare solutions but also new drug development through an independent microbiome-based new drug pipeline, using this Preliminary Unicorn selection as an opportunity."

Meanwhile, HEM Pharma is preparing for a KOSDAQ listing, having selected Samsung Securities as the lead manager for its IPO.

This content was produced with the assistance of AI translation services.